FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1964522360> ?p ?o ?g. }

• W1964522360 endingPage "629S" @default.
• W1964522360 startingPage "593S" @default.
• W1964522360 abstract "This chapter about antithrombotic therapy for valvular heart disease is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patient values might lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2008; 133[suppl]:123S–131S). Among the key recommendations in this chapter are the following: for patients with rheumatic mitral valve disease complicated singly or in combination by the presence of atrial fibrillation (AF), previous systemic embolism, or left atrial thrombus, we recommend vitamin K antagonist (VKA) therapy (Grade 1A). For patients with rheumatic mitral valve disease and normal sinus rhythm, without left atrial enlargement, we do not suggest antithrombotic therapy unless a separate indication exists (Grade 2C). For patients with mitral valve prolapse (MVP), not complicated by AF, who have not had systemic embolism, unexplained transient ischemic attacks, or ischemic stroke, we recommend against antithrombotic therapy (Grade 1C). In patients with mitral annular calcification complicated by systemic embolism or ischemic stroke, we recommend antiplatelet agent (APA) therapy (Grade 1B). For patients with isolated calcific aortic valve disease, we suggest against antithrombotic therapy (Grade 2C). But, for those with aortic valve disease who have experienced ischemic stroke, we suggest APA therapy (Grade 2C). For patients with stroke associated with aortic atherosclerotic lesions, we recommend low-dose aspirin (ASA) therapy (Grade 1C). For patients with cryptogenic ischemic stroke and a patent foramen ovale (PFO), we recommend APA therapy (Grade 1A). For patients with mechanical heart valves, we recommend VKA therapy (Grade 1A). For patients with mechanical heart valves and history of vascular disease or who have additional risk factors for thromboembolism, we recommend the addition of low-dose aspirin ASA to VKA therapy (Grade 1B). We suggest ASA not be added to long-term VKA therapy in patients with mechanical heart valves who are at particularly high risk of bleeding (Grade 2C). For patients with bioprosthetic heart valves, we recommend ASA (Grade 1B). For patients with bioprosthetic heart valves and additional risk factors for thromboembolism, we recommend VKA therapy (Grade 1C). For patients with infective endocarditis, we recommend against antithrombotic therapy, unless a separate indication exists (Grade 1B). This chapter about antithrombotic therapy for valvular heart disease is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs. Grade 2 suggests that individual patient values might lead to different choices (for a full understanding of the grading see Guyatt et al, CHEST 2008; 133[suppl]:123S–131S). Among the key recommendations in this chapter are the following: for patients with rheumatic mitral valve disease complicated singly or in combination by the presence of atrial fibrillation (AF), previous systemic embolism, or left atrial thrombus, we recommend vitamin K antagonist (VKA) therapy (Grade 1A). For patients with rheumatic mitral valve disease and normal sinus rhythm, without left atrial enlargement, we do not suggest antithrombotic therapy unless a separate indication exists (Grade 2C). For patients with mitral valve prolapse (MVP), not complicated by AF, who have not had systemic embolism, unexplained transient ischemic attacks, or ischemic stroke, we recommend against antithrombotic therapy (Grade 1C). In patients with mitral annular calcification complicated by systemic embolism or ischemic stroke, we recommend antiplatelet agent (APA) therapy (Grade 1B). For patients with isolated calcific aortic valve disease, we suggest against antithrombotic therapy (Grade 2C). But, for those with aortic valve disease who have experienced ischemic stroke, we suggest APA therapy (Grade 2C). For patients with stroke associated with aortic atherosclerotic lesions, we recommend low-dose aspirin (ASA) therapy (Grade 1C). For patients with cryptogenic ischemic stroke and a patent foramen ovale (PFO), we recommend APA therapy (Grade 1A). For patients with mechanical heart valves, we recommend VKA therapy (Grade 1A). For patients with mechanical heart valves and history of vascular disease or who have additional risk factors for thromboembolism, we recommend the addition of low-dose aspirin ASA to VKA therapy (Grade 1B). We suggest ASA not be added to long-term VKA therapy in patients with mechanical heart valves who are at particularly high risk of bleeding (Grade 2C). For patients with bioprosthetic heart valves, we recommend ASA (Grade 1B). For patients with bioprosthetic heart valves and additional risk factors for thromboembolism, we recommend VKA therapy (Grade 1C). For patients with infective endocarditis, we recommend against antithrombotic therapy, unless a separate indication exists (Grade 1B)." @default.
• W1964522360 created "2016-06-24" @default.
• W1964522360 creator A5037218394 @default.
• W1964522360 creator A5059420362 @default.
• W1964522360 creator A5071587808 @default.
• W1964522360 creator A5083325667 @default.
• W1964522360 date "2008-06-01" @default.
• W1964522360 modified "2023-10-16" @default.
• W1964522360 title "Valvular and Structural Heart Disease" @default.
• W1964522360 cites W106163320 @default.
• W1964522360 cites W1177894438 @default.
• W1964522360 cites W1415814174 @default.
• W1964522360 cites W1463762514 @default.
• W1964522360 cites W1485599119 @default.
• W1964522360 cites W1493823773 @default.
• W1964522360 cites W1496217454 @default.
• W1964522360 cites W1515396501 @default.
• W1964522360 cites W183477746 @default.
• W1964522360 cites W1963641595 @default.
• W1964522360 cites W1965466111 @default.
• W1964522360 cites W1966372840 @default.
• W1964522360 cites W1966501843 @default.
• W1964522360 cites W1967937963 @default.
• W1964522360 cites W1968994822 @default.
• W1964522360 cites W1969639127 @default.
• W1964522360 cites W1969928268 @default.
• W1964522360 cites W1971340924 @default.
• W1964522360 cites W1971343276 @default.
• W1964522360 cites W1971510082 @default.
• W1964522360 cites W1973855108 @default.
• W1964522360 cites W1974309646 @default.
• W1964522360 cites W1974595529 @default.
• W1964522360 cites W1975530867 @default.
• W1964522360 cites W1975769887 @default.
• W1964522360 cites W1976485708 @default.
• W1964522360 cites W1977163110 @default.
• W1964522360 cites W1978170036 @default.
• W1964522360 cites W1979283858 @default.
• W1964522360 cites W1979309627 @default.
• W1964522360 cites W1980859840 @default.
• W1964522360 cites W1981746689 @default.
• W1964522360 cites W1983154538 @default.
• W1964522360 cites W1986266902 @default.
• W1964522360 cites W1986793800 @default.
• W1964522360 cites W1987095761 @default.
• W1964522360 cites W1987602525 @default.
• W1964522360 cites W1987927838 @default.
• W1964522360 cites W1988501163 @default.
• W1964522360 cites W1990447764 @default.
• W1964522360 cites W1990852664 @default.
• W1964522360 cites W1991069488 @default.
• W1964522360 cites W1991549653 @default.
• W1964522360 cites W1992180704 @default.
• W1964522360 cites W1994231358 @default.
• W1964522360 cites W1994580388 @default.
• W1964522360 cites W1996215601 @default.
• W1964522360 cites W1996817337 @default.
• W1964522360 cites W1996853066 @default.
• W1964522360 cites W1997249405 @default.
• W1964522360 cites W1997413458 @default.
• W1964522360 cites W1998421545 @default.
• W1964522360 cites W2000328367 @default.
• W1964522360 cites W2000674953 @default.
• W1964522360 cites W2000751230 @default.
• W1964522360 cites W2004337162 @default.
• W1964522360 cites W2006293350 @default.
• W1964522360 cites W2007650238 @default.
• W1964522360 cites W2007887497 @default.
• W1964522360 cites W2008617085 @default.
• W1964522360 cites W2008635765 @default.
• W1964522360 cites W2010022313 @default.
• W1964522360 cites W2011071560 @default.
• W1964522360 cites W2011829574 @default.
• W1964522360 cites W2012309806 @default.
• W1964522360 cites W2014256245 @default.
• W1964522360 cites W2018093494 @default.
• W1964522360 cites W2019799671 @default.
• W1964522360 cites W2021556603 @default.
• W1964522360 cites W2022395232 @default.
• W1964522360 cites W2022763183 @default.
• W1964522360 cites W2024778708 @default.
• W1964522360 cites W2025418198 @default.
• W1964522360 cites W2027473028 @default.
• W1964522360 cites W2027538725 @default.
• W1964522360 cites W2027832110 @default.
• W1964522360 cites W2028916401 @default.
• W1964522360 cites W2029550334 @default.
• W1964522360 cites W2030140807 @default.
• W1964522360 cites W2032418317 @default.
• W1964522360 cites W2032483714 @default.
• W1964522360 cites W2033527018 @default.
• W1964522360 cites W2033648969 @default.
• W1964522360 cites W2034403639 @default.
• W1964522360 cites W2035545749 @default.
• W1964522360 cites W2035656335 @default.
• W1964522360 cites W2037400498 @default.
• W1964522360 cites W2038235906 @default.
• W1964522360 cites W2038738595 @default.

• next